Cargando…

The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis

The impact of Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant, which causes hepatocellular fat retention by altering lipoprotein secretion, on liver damage and metabolic traits in chronic hepatitis C patients is still debated. We performed a systematic review and meta-analysis to clarify...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhengtao, Que, Shuping, Zhou, Lin, Zheng, Shusen, Romeo, Stefano, Mardinoglu, Adil, Valenti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571206/
https://www.ncbi.nlm.nih.gov/pubmed/28839198
http://dx.doi.org/10.1038/s41598-017-09548-9
_version_ 1783259312771039232
author Liu, Zhengtao
Que, Shuping
Zhou, Lin
Zheng, Shusen
Romeo, Stefano
Mardinoglu, Adil
Valenti, Luca
author_facet Liu, Zhengtao
Que, Shuping
Zhou, Lin
Zheng, Shusen
Romeo, Stefano
Mardinoglu, Adil
Valenti, Luca
author_sort Liu, Zhengtao
collection PubMed
description The impact of Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant, which causes hepatocellular fat retention by altering lipoprotein secretion, on liver damage and metabolic traits in chronic hepatitis C patients is still debated. We performed a systematic review and meta-analysis to clarify this relationship. Four studies with a total of 4325 patients were included. The risk of histologically-determined advanced steatosis, fibrosis, and cirrhosis (but not of severe inflammation) were increased in carriers of the TM6SF2 variant (P < 0.05). Unlike the inconsistent association with steatosis severity, due to the confounding effect of infection by the genotype-3 hepatitis C virus, the TM6SF2 variant was robustly associated with advanced fibrosis (OR = 1.07; 95% confidence interval [CI] = 1.01–1.14) and in particular with cirrhosis (OR = 2.05; 95% CI = 1.39–3.02). Regarding metabolic features, individuals positive for the TM6SF2 variant exhibited 5.8–12.0% lower levels of circulating triglycerides and non-HDL cholesterol (P < 0.05). Carriers of the variant were leaner, but there was high heterogeneity across studies (I(2) = 97.2%). No significant association was observed between the TM6SF2 variant and insulin resistance or hepatitis C viral load (both P > 0.05). In conclusion, the TM6SF2 E167K variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis C. Conversely, this variant reduces circulating atherogenic lipid fractions.
format Online
Article
Text
id pubmed-5571206
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55712062017-09-01 The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis Liu, Zhengtao Que, Shuping Zhou, Lin Zheng, Shusen Romeo, Stefano Mardinoglu, Adil Valenti, Luca Sci Rep Article The impact of Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant, which causes hepatocellular fat retention by altering lipoprotein secretion, on liver damage and metabolic traits in chronic hepatitis C patients is still debated. We performed a systematic review and meta-analysis to clarify this relationship. Four studies with a total of 4325 patients were included. The risk of histologically-determined advanced steatosis, fibrosis, and cirrhosis (but not of severe inflammation) were increased in carriers of the TM6SF2 variant (P < 0.05). Unlike the inconsistent association with steatosis severity, due to the confounding effect of infection by the genotype-3 hepatitis C virus, the TM6SF2 variant was robustly associated with advanced fibrosis (OR = 1.07; 95% confidence interval [CI] = 1.01–1.14) and in particular with cirrhosis (OR = 2.05; 95% CI = 1.39–3.02). Regarding metabolic features, individuals positive for the TM6SF2 variant exhibited 5.8–12.0% lower levels of circulating triglycerides and non-HDL cholesterol (P < 0.05). Carriers of the variant were leaner, but there was high heterogeneity across studies (I(2) = 97.2%). No significant association was observed between the TM6SF2 variant and insulin resistance or hepatitis C viral load (both P > 0.05). In conclusion, the TM6SF2 E167K variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis C. Conversely, this variant reduces circulating atherogenic lipid fractions. Nature Publishing Group UK 2017-08-24 /pmc/articles/PMC5571206/ /pubmed/28839198 http://dx.doi.org/10.1038/s41598-017-09548-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Zhengtao
Que, Shuping
Zhou, Lin
Zheng, Shusen
Romeo, Stefano
Mardinoglu, Adil
Valenti, Luca
The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title_full The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title_fullStr The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title_full_unstemmed The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title_short The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
title_sort effect of the tm6sf2 e167k variant on liver steatosis and fibrosis in patients with chronic hepatitis c: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571206/
https://www.ncbi.nlm.nih.gov/pubmed/28839198
http://dx.doi.org/10.1038/s41598-017-09548-9
work_keys_str_mv AT liuzhengtao theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT queshuping theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT zhoulin theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT zhengshusen theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT romeostefano theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT mardinogluadil theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT valentiluca theeffectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT liuzhengtao effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT queshuping effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT zhoulin effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT zhengshusen effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT romeostefano effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT mardinogluadil effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis
AT valentiluca effectofthetm6sf2e167kvariantonliversteatosisandfibrosisinpatientswithchronichepatitiscametaanalysis